A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients

A Phase III, Randomized, Open-label, Non-inferiority Study Comparative of Formoterol/Fluticasone Eurofarma 12/250 µg, Foraseq® 12/400 µg and Fluticasone 500 µg in Asthma Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01202084

Enrollment

222

Registered

2010-09-15

Start date

2012-01-31

Completion date

2012-11-30

Last updated

2015-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The primary objective will be to compare the impact of the study formulations on pulmonary function in persistent asthma carriers.

Interventions

DRUGFormoterol/Fluticasone

DRUGForaseq®

DRUGFluticasone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Sign the ICF * Age ≥ 12 years * Persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month, with the ACQ-745 test (see Appendix C) ≤ 3.0 * Current use of inhaled corticosteroid (beclomethasone dipropionate dose of up to 1000 µg), associated or not with long-term β2-adrenergic agents and breakthrough medication (salbutamol or equivalent) * Initial FEV1 of at least 40% of the predicted normal value * Serum cortisol assessment within normal values.

Exclusion criteria

* Use of oral or parenteral corticosteroid within the 3 months prior to study beginning * Requirement of admission due to asthma within the 3 months prior to study beginning * Presence of active smoking, defined as the use of cigarette, pipe, cigar or any form of smoking at any amount within the last 3 months * Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological, psychiatric or chronic respiratory disease other than asthma * Recent (\< 6 months) or predicted participation during this study in other clinical studies involving drugs of any nature or in studies of any form of intervention for treating asthma * Intolerance or allergy to any of the components of the drugs assessed in the study * Pregnancy or lactation * Chronic use of β-blocker medications, per routine oral or intravenous route, or also as ophthalmic solutions

Design outcomes

Primary

Measure	Time frame
Forced expiratory volume in 1 second (FEV1) at final visit.	12 weeks

Secondary

Measure	Time frame
Peak expiratory flow (PEF)	12 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026